Simbarashe Zvada

815 total citations
12 papers, 276 citations indexed

About

Simbarashe Zvada is a scholar working on Infectious Diseases, Epidemiology and Pharmacology. According to data from OpenAlex, Simbarashe Zvada has authored 12 papers receiving a total of 276 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Infectious Diseases, 5 papers in Epidemiology and 3 papers in Pharmacology. Recurrent topics in Simbarashe Zvada's work include Pneumocystis jirovecii pneumonia detection and treatment (4 papers), Antibiotics Pharmacokinetics and Efficacy (3 papers) and HIV/AIDS drug development and treatment (3 papers). Simbarashe Zvada is often cited by papers focused on Pneumocystis jirovecii pneumonia detection and treatment (4 papers), Antibiotics Pharmacokinetics and Efficacy (3 papers) and HIV/AIDS drug development and treatment (3 papers). Simbarashe Zvada collaborates with scholars based in South Africa, United Kingdom and Zimbabwe. Simbarashe Zvada's co-authors include Helen McIlleron, Ulrika S. H. Simonsson, Paolo Denti, Collen Masimirembwa, Prosper Chonzi, Charles F. B. Nhachi, Amina Jindani, Mark Hatherill, Thomas S. Harrison and Lubbe Wiesner and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, Clinical Pharmacology & Therapeutics and Journal of Antimicrobial Chemotherapy.

In The Last Decade

Simbarashe Zvada

12 papers receiving 273 citations

Peers

Simbarashe Zvada
Annie Fang United States
Neesha Rockwood United Kingdom
Bryan McGee United States
L. Trentini Italy
Jerry Jean Stambaugh United States
Yoninah Cramer United States
Gong Shen United States
Mohammed Janabi Tanzania
Rosa Ruiz-Valderas Spain
Michael Zilly Germany
Annie Fang United States
Simbarashe Zvada
Citations per year, relative to Simbarashe Zvada Simbarashe Zvada (= 1×) peers Annie Fang

Countries citing papers authored by Simbarashe Zvada

Since Specialization
Citations

This map shows the geographic impact of Simbarashe Zvada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simbarashe Zvada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simbarashe Zvada more than expected).

Fields of papers citing papers by Simbarashe Zvada

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simbarashe Zvada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simbarashe Zvada. The network helps show where Simbarashe Zvada may publish in the future.

Co-authorship network of co-authors of Simbarashe Zvada

This figure shows the co-authorship network connecting the top 25 collaborators of Simbarashe Zvada. A scholar is included among the top collaborators of Simbarashe Zvada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simbarashe Zvada. Simbarashe Zvada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
2.
Sun, Qin, Shirley K. Seo, Simbarashe Zvada, Chao Liu, & Kellie S. Reynolds. (2020). Does Hepatic Impairment Affect the Exposure of Monoclonal Antibodies?. Clinical Pharmacology & Therapeutics. 107(5). 1256–1262. 14 indexed citations
3.
Richardson, Nicholas C., Gregory H. Reaman, Anusha Ande, et al.. (2020). FDA approval summary: Dalteparin for the treatment of symptomatic venous thromboembolism in pediatric patients. Pediatric Blood & Cancer. 67(12). e28688–e28688. 3 indexed citations
4.
Zvada, Simbarashe, Paolo Denti, Mark Hatherill, et al.. (2019). A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine. Antimicrobial Agents and Chemotherapy. 63(4). 20 indexed citations
5.
6.
Zvada, Simbarashe, Paolo Denti, P. R. Donald, et al.. (2014). Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses. Journal of Antimicrobial Chemotherapy. 69(5). 1339–1349. 48 indexed citations
7.
Zvada, Simbarashe, Paolo Denti, Frederick A. Sirgel, et al.. (2013). Moxifloxacin Population Pharmacokinetics and Model-Based Comparison of Efficacy between Moxifloxacin and Ofloxacin in African Patients. Antimicrobial Agents and Chemotherapy. 58(1). 503–510. 35 indexed citations
8.
Pillai, Goonaseelan, Geraint Davies, Paolo Denti, et al.. (2013). Pharmacometrics: Opportunity for Reducing Disease Burden in the Developing World: The Case of Africa. CPT Pharmacometrics & Systems Pharmacology. 2(8). 1–4. 18 indexed citations
9.
Zvada, Simbarashe, Paolo Denti, Hennie Geldenhuys, et al.. (2012). Moxifloxacin Population Pharmacokinetics in Patients with Pulmonary Tuberculosis and the Effect of Intermittent High-Dose Rifapentine. Antimicrobial Agents and Chemotherapy. 56(8). 4471–4473. 29 indexed citations
10.
Zvada, Simbarashe, Jan‐Stefan van der Walt, Peter J. Smith, et al.. (2010). Effects of Four Different Meal Types on the Population Pharmacokinetics of Single-Dose Rifapentine in Healthy Male Volunteers. Antimicrobial Agents and Chemotherapy. 54(8). 3390–3394. 27 indexed citations
11.
Thelingwani, Roslyn, Simbarashe Zvada, Hugues Dolgos, Anna‐Lena Ungell, & Collen Masimirembwa. (2009). In Vitro and in Silico Identification and Characterization of Thiabendazole as a Mechanism-Based Inhibitor of CYP1A2 and Simulation of Possible Pharmacokinetic Drug-Drug Interactions. Drug Metabolism and Disposition. 37(6). 1286–1294. 21 indexed citations
12.
Zvada, Simbarashe, et al.. (2009). An Experimental Pharmacokinetic Computer Program to Predict Potential Drug-Drug Interactions. 3. 8–16. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Annie Fang Breakdown of academic impact, for papers by Neesha Rockwood Breakdown of academic impact, for papers by Bryan McGee Breakdown of academic impact, for papers by L. Trentini Breakdown of academic impact, for papers by Jerry Jean Stambaugh Breakdown of academic impact, for papers by Yoninah Cramer Breakdown of academic impact, for papers by Gong Shen Breakdown of academic impact, for papers by Mohammed Janabi Breakdown of academic impact, for papers by Rosa Ruiz-Valderas Breakdown of academic impact, for papers by Michael Zilly
Rankless by CCL
2026